Mark Lampert’s Biotechnology Value Fund recently filed its 13F with the U.S. Securities and Exchange Commission for the reporting period of March 31. The firm’s public equity portfolio stood $478.24 million, while it has $999.89 million in assets under management. Since its foundation in 1993, Biotechnology Value Fund has consistently worked to develop concentrated and long-term investments with a focus on small-cap biotechnology companies. Insider Monkey has a keen interest in the activities of the San Francisco-based investment firm and has been tracking its activities. In this article, we focus on three of its top small-cap picks, which are Array Biopharma Inc (NASDAQ:ARRY), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), and Forward Pharma A/S (NASDAQ:FWP).
Read more at http://www.insidermonkey.com/blog/one-of-mark-lamperts-small-cap-biotech-picks-has-returned-84-this-year-and-its-not-done-yet-352976/#04F0imXjACu5pvLS.99
At the end of the first quarter, Biotechnology Value Fund held a total of 9.41 million shares of Array Biopharma Inc (NASDAQ:ARRY) valued at $69.32 million. This represented a decrease compared to the end of the fourth quarter of 2014 when it held a total of 11.77 million shares, although the value of the position has actually increased since then. That’s because shares of the biotechnology company, which recently sold its Longmont facility, chemistry, manufacturing and controls (CMC), to Accuratus Lab Services Inc, gained over 50% during the first quarter of the year. Array recently ranked 419 on a list of the fastest-growing companies released last year by Deloitte Technology Fast 500, with the firm having an annual revenue growth of 179%. Seven Wall Street analysts have given the stock an average short term price target of $11.00, signifying yet more upside of another 50%. Analysts will be keen to know whether the stock will pull a surprise like it did in its most recent quarterly report where it delivered a 42.11% earnings surprise factor.
Sentiment: Strong Buy
Some one bought 7.00 calls for .20 a couple of weeks ago and it has been going down since then I wonder what those calls are selling for now?
Snake oil gets deleted when the sale en spouts of about The next. Big thing
Ronny the yak needs to drink some snake oil the same stuff he has been dishing out to investors
We're are the Deerfield investors?. ya gotta wonder if Ronnny Boy. Has a Rabbi. Preying for him?
What a FAILRE. Over 4 years of collecting a paycheck. Without any marked performance.
How can I get That Deal?
Amazing. How. Greece and the Euro can effect the Wall Strret. Gang. Of 90 year olds
I can not. Get a handle on the way some react. To IMF.
Hope for better days ARRY needs a New CEO. Before it crashes and burns
True ARRY has Good pipeline but the best ship must have a captain to steer the ship The CEO has not delivered results only YAK for 4-years he has. Collected investors bucks with. Very little in return the stock price increase is caused by ratings based on trials No real leadership and the boat. drifts until it hits rocks
ARRY Desperately needs Leadership Not Smoke and MirrorPony SHOW Deerfield others need to put the pressure on BOD& Chairman for positive change
Hate being right, well, since I gave both upside and down side moves, ummm, the downside played out. Need news to get this puppy moving.